Updated:
Zevra Therapeutics
Neil F. McFarlane leads Zevra Therapeutics, a publicly traded rare disease company formed in 2023 via the merger of KemPharm and Orphazyme.
Zevra Therapeutics
Zevra Therapeutics was formed in February 2023 when KemPharm, Inc., a publicly traded specialty pharmaceutical company focused on prodrug development, completed its acquisition of Orphazyme A/S, a Danish biotech emerging from bankruptcy with one FDA-approved asset, Miplyffa (arimoclomol), for Niemann-Pick disease type C. Neil F. McFarlane, who had been operating as CEO of KemPharm, retained the top role. The combined company renamed itself Zevra Therapeutics and relocated its corporate headquarters to Celebration, Florida. The structure is that of a commercial-stage rare disease consolidator, not a traditional family office or investment manager. The company commercializes and develops therapies for rare diseases with limited or no treatment options. Its current portfolio includes Miplyffa (arimoclomol), the firm's sole FDA-approved product for Niemann-Pick disease type C, a progressive neurodegenerative lysosomal storage disorder. A second near-term pipeline asset, KP1077 (serdexmethylphenidate), is in late-stage development for idiopathic hypersomnia and narcolepsy. The legacy KemPharm pipeline generated Azstarys, a once-daily ADHD prodrug of dexmethylphenidate, commercialized by Corium, Inc. since 2021 and partnered with Commave Therapeutics. Zevra’s geographic footprint centers on the U.S. market, with Miplyffa launched commercially in September 2023 following FDA approval that same month. Zevra employs a lean team typical of late-stage biotechs, with financial decision-making centralized under McFarlane and CFO R. LaDuane Clifton. In addition to its therapeutic pipeline, Zevra's predecessor company KemPharm generated revenue through royalty streams on Azstarys, which provides non-dilutive capital to fund rare disease development. In May 2024, Zevra announced the FDA acceptance of its New Drug Application for arimoclomol and secured a priority review voucher upon approval — a secondary asset it could monetize (per the firm, May 2024). The company has no disclosed Philanthropic foundation or family office structure, operating strictly as a for-profit public entity (Nasdaq: ZVRA). Zevra's corporate architecture is structurally unusual: it was built through a reverse merger in which a smaller, distressed biotech (Orphazyme) served as the vehicle to retool a prodrug-focused company into a rare disease platform. This is a roll-up strategy applied to pharmaceutical intellectual property — distinct from both traditional venture capital-funded biotechs and large pharma spinouts. The resulting entity holds a marketed rare disease drug, a licensing-derived ADHD franchise, and a single late-stage CNS asset, creating a barbell portfolio financed by royalty income rather than recurrent equity raises.
General information
Firm type
Asset Manager
Year founded
2006
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Celebration
Corporate office
Celebration, FL, United States
Principals
Neil F. McFarlane
President and Chief Executive Officer
R. LaDuane Clifton
Chief Financial Officer
Sector focus
Frequently asked questions
How was Zevra Therapeutics formed?
Zevra Therapeutics was created in February 2023 through the merger of KemPharm, a CNS-focused prodrug developer, and Orphazyme A/S, a Danish biotech that had recently emerged from bankruptcy. The transaction was structured as KemPharm acquiring Orphazyme, followed by an immediate corporate name change. The merger gave KemPharm a rare disease asset, Miplyffa, and a repositioned identity that shifted the company's therapeutic focus away from its legacy CNS pipeline. It remains a publicly traded entity on Nasdaq under the ticker 'ZVRA'.
What is Zevra's only FDA-approved product?
Miplyffa (arimoclomol) is Zevra's sole FDA-approved product, authorized in September 2023 for the treatment of Niemann-Pick disease type C, a rare, progressive neurodegenerative lysosomal storage disorder. The drug originated in the Orphazyme pipeline that Zevra acquired in the 2023 merger. As part of the approval, Zevra also received a Rare Pediatric Disease Priority Review Voucher, which it can sell to another pharmaceutical company as a secondary monetary asset.
Who makes the key investment and strategic decisions at Zevra?
Neil F. McFarlane, who serves as President and CEO, is the central decision-maker for corporate strategy and capital allocation. He has held the chief executive role since the Zevra-KemPharm era and retained it through the Orphazyme merger. CFO R. LaDuane Clifton manages the financial operations, including the royalty revenue streams from the legacy ADHD drug Azstarys.
Does Zevra operate as a venture firm or family office?
No. Zevra is a publicly traded commercial-stage biopharmaceutical company, not a venture capital fund, family office, or investment manager. It develops and commercializes its own therapeutic assets, funded in part by royalty income from Azstarys, a partnered ADHD product. While it acquires clinical-stage assets — as it did with the Orphazyme portfolio — it functions as an operating company consolidating rare disease programs.
How is Zevra funded?
Zevra funds its operations through a combination of commercial revenue from Miplyffa, royalty payments from the Azstarys ADHD franchise commercialized by Corium Inc., and periodic equity financings via the public markets. The Azstarys royalty stream is particularly notable because it provides non-dilutive capital, reducing the pressure for constant equity raises typical of pre-revenue biotechs.
What other assets does Zevra have beyond Miplyffa?
Zevra's pipeline includes KP1077 (serdexmethylphenidate), a prodrug in late-stage development for idiopathic hypersomnia and narcolepsy. The company also retains an economic interest in Azstarys, an FDA-approved once-daily ADHD treatment developed through the legacy KemPharm prodrug platform. That drug is now marketed by Corium Inc. and partnered with Commave Therapeutics, giving Zevra a royalty-based asset that is separate from its rare disease focus.
What is Zevra's relationship to KemPharm and Orphazyme?
Zevra is the direct successor company to KemPharm, Inc., which acquired Orphazyme A/S in a stock-for-stock transaction in February 2023. Rather than operate the two entities separately, leadership merged the pipelines, adopted a new corporate name, and relocated the headquarters. The legacy KemPharm CNS assets remain in the portfolio, but the company's public identity and therapeutic focus shifted to rare diseases, reflecting the Orphazyme acquisition.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: